An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-fourths of treated patients.
|Articles|November 19, 2021
Pharmacy Clinical Pearl of the Day: Hodgkin Lymphoma
Author(s)Saro Arakelians, PharmD
Hodgkin lymphoma is most common in people between 20 and 40 years of age and those over 55 years of age.
Advertisement
Clinical Pearl of the Day: Hodgkin Lymphoma
Hodgkin lymphoma is a cancer of the lymphatic system, which is part of the immune system.
Insight:
- Hodgkin lymphoma may affect people of any age but is most common in people between 20 and 40 years of age and those over 55 years of age.
- Symptoms include painless swelling of lymph nodes in the neck, armpits or groin, persistent fatigue, fever, night sweats, unexplained weight loss, severe itching, and increased sensitivity to alcohol or pain.
- Subtypes of classical Hodgkin lymphoma include nodular sclerosis Hodgkin lymphoma, mixed cellularity Hodgkin lymphoma, lymphocyte-depleted Hodgkin lymphoma, and lymphocyte-rich Hodgkin lymphoma.
- Risk factors include age between 15 to 30 years and over 55 years, family history of lymphoma, being male, and past Epstein-Barr infection
- Diagnosis includes physical exam, blood tests, imaging tests, removing the lymph node for testing and removing a sample of bone marrow for testing
- Treatment includes chemotherapy, radiation therapy and bone marrow transplant
- Chemotherapy options include:
Sources:
Advertisement
Related to this article
Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
Fixed-duration KRd slowed progression in high-risk smoldering myeloma, but high rates of severe toxicity temper enthusiasm.
Long-term CASSIOPEIA Registry results show that daratumumab maintenance supports sustained minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma.
Infection prevention during bispecific antibody treatment requires pharmacists to coordinate baseline screening, antimicrobial prophylaxis, immunoglobulin monitoring, vaccination, and rapid evaluation of suspected infections.
September’s hematology coverage examined a new definition of myeloma cure, patient preferences for treatment delivery, and emerging strategies for deepening responses.
A detailed LINKER-MM1 analysis found that cytokine release syndrome (CRS) with linvoseltamab occurred early, was predominantly low grade, and became less frequent with successive step-up and full doses.
A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Intensive Chemotherapy in Combination With Quizartinib Versus Midostaurin for FLT3-ITD Mutated Acute Myeloid Leukemia: A Multicenter Cohort Study
2
September 2026 in Pain Management: 4 Updates on Treatment and Pharmacy Practice
3
Orforglipron Edges Oral Semaglutide 25 mg in T2D, Indirect Comparison Finds
4
Retatrutide Cuts Weight Up to 18.8% in Adults With T2D, Obesity
5